Medpace (MEDP) Stock Drops Despite Market Gains: Important Facts to Note

Company Performance - Medpace's stock closed at $588.05, down 3.01%, underperforming the S&P 500's gain of 0.03% on the same day [1] - Over the past month, Medpace's stock has increased by 6.02%, outperforming the Medical sector's slight loss of 0.01% and the S&P 500's gain of 0.6% [1] Upcoming Earnings - Medpace is set to release its earnings report on February 9, 2026, with an expected EPS of $4.18, reflecting a 13.9% increase year-over-year [2] - Revenue is anticipated to reach $681.17 million, indicating a 26.94% rise compared to the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, representing increases of 17.18% and no change, respectively, from the previous year [3] - Recent revisions to analyst forecasts for Medpace are crucial as they reflect short-term business trends and can indicate analysts' positive outlook on the company's health and profitability [3] Valuation Metrics - Medpace currently has a Forward P/E ratio of 36.47, which is significantly higher than the industry average Forward P/E of 16.37 [5] - The company has a PEG ratio of 2.04, compared to the industry average PEG ratio of 1.92 [6] Industry Ranking - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 188, placing it in the bottom 24% of over 250 industries [6] - The Zacks Industry Rank evaluates the performance of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]